FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 15:09:17 2024-06-05 EDT | ||
| 7.75 EUR | -3.73% |
|
| Current month | -5.96% | ||
| 1 month | -20.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 7.75 | -3.73% |
| 24-06-04 | 8.05 | -4.85% |
| 24-06-03 | 8.46 | -1.17% |
| 24-05-31 | 8.56 | -1.38% |
| 24-05-30 | 8.68 | +0.23% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 03:09 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1SF2 |
| ISIN | DE000MG1SF25 |
| Date issued | 2024-04-05 |
| Strike | 1,404 kr |
| Maturity | Unlimited |
| Parity | 7.54 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.59 € |
|---|---|
| Lowest since issue | 7.74 € |
| Spread | 0.06 € |
| Spread % | 0.77% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Certificates
- Certificat
